Dysregulated miR-137 and its target EGFR contribute to the progression of pituitary adenomas

Abstract Pituitary adenomas (PAs) hypersecrete hormones or cause mass effect symptoms, with 10%–35% patients showing resistance to standard therapies. Targeting epidermal growth factor receptor (EGFR) has significantly improved the clinical outcome in many cancers. In this study, immunochemistry results showed that EGFR associated H-scores in 116 PA samples were higher than those in pituitary glands, and that p21, p27-and Wif-1 associated H-scores were lower (P